SEARCH

SEARCH BY CITATION

References

  • 1
    Ghany MG, Strader DB, Thomas DL, Seeff LB. American association for the study of liver diseases diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 133574.
  • 2
    Welker MW, Zeuzem S. Occult hepatitis C: how convincing are the current data? Hepatology 2009; 49: 66575.
  • 3
    Bartolomé J, López-Alcorocho JM, Castillo I, et al. Ultracentrifugation of serum samples allows detection of hepatitis C virus RNA in patients with occult hepatitis C. J Virol 2007; 81: 77105.
  • 4
    Radkowski M, Horban A, Gallegos-Orozco JF, et al. Evidence for viral persistence in patients who test positive for anti-hepatitis C virus antibodies and have normal alanine aminotransferase levels. J Infect Dis 2005; 191: 17303.
  • 5
    Martinot-Peignoux M, Stern C, Maylin S, et al. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin. Hepatology 2010; 51: 11226.
  • 6
    Chavalitdhamrong D, Tanwandee T. Long term out-comes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. World J Gastroenterol 2006; 12: 55325.
  • 7
    Marcellin P, Boyer N, Gervais A, et al. Long-tem histological improvement and loss of detectable intrahepatic HC RNA in patients with chronic hepatitis C and sustained response to interferon alfa therapy. Ann Int Med 1997; 127: 87581.
  • 8
    Zeuzem S, Diago M, PEGASYS Study NR16071 Investigator Group et al. Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 2004; 127: 172432.
  • 9
    Alberti A. Towards more individualised management of hepatitis C virus patients with initially or persistently normal alanineaminotransferase levels. J Hepatol 2005; 42: 26674.
  • 10
    Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 51724.
  • 11
    Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 130313.
  • 12
    Toccaceli F, laghi V, Capurso L, et al. Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon. J Viral Hepat 2003; 10: 12633.
  • 13
    Veldt BJ, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53: 15048.
  • 14
    Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135: 8219.
  • 15
    George SL, Bacon BR, Brunt EM, et al. Clinical, virological, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follw-up of 150 patients. Heatology 2009; 49: 72938.
  • 16
    Poynard T, Ngo Y, Munteanu M, et al. Biomarkers of liver injury for hepatitis clinical trials: a meta-analysis of longitudinal studies. Antivir Ther 2010; 15: 61731.
  • 17
    Wang JH, Changchien CS, Hung CH, et al. Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: longitudinal study using FibroScan. J Gastroenterol Hepatol 2010; 25: 9649.
  • 18
    Arora S, O'Brien C, Zeuzem S, et al. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life. J Gastroenterol Hepatol 2006; 21: 40612.
  • 19
    Omland LH, Krarup H, DANVIR Cohort Study et al. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study. J Hepatol 2010; 53: 3642.
  • 20
    Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 2010; 52: 6527.
  • 21
    Bruno S, Crosignani A, Facciotto C, et al. Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class. A hepatitis C virus-induced cirrhosis a 12-year prospective follow-up study. Hepatology 2010; 51: 206976.
  • 22
    Shiffman ML. Impact of peginterferon maintenance therapy on the risk of developing hepatocellular carcinoma in patients with chronic hepatitis C virus. Oncology 2010; 78 (Suppl. 1): 116.
  • 23
    Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359: 242941.